Antimicrobial Susceptibility Testing Market Size, Share, Growth Analysis, By Test type(Phenotypic testing, genotypic testing, and rapid testing), By End user(Hospitals and diagnostic laboratories, research and academic institutes, and pharmaceutical and biotechnology companies), By Product type(Instruments, reagents and kits, and software and services), By Region - Industry Forecast 2024-2031

Antimicrobial Susceptibility Testing Market Drivers

Rising Antimicrobial Resistance and Cases of Infectious Diseases 

• The growth of AMR is a major threat to global health. Health organizations and authorities are focusing on the need for efficient AST to observe resistance patterns. This helps in the guidance of treatment decisions and encouraging the use of antibiotics. Also, growing cases of infectious diseases are supported by factors like travel, urbanization, and population growth that demand treatment and diagnosis. This drives the demand for effective and reliable AST. 

Growing Awareness for Infection Control 

• Rising awareness among patients and healthcare professionals regarding infection control methods is fueling the use of AST. Hospitals are emphasizing AST to decrease the cases of HAIs. Also, the growth of healthcare facilities, especially in the developing economies is supporting the demand for AST. Moreover, better access to diagnostic services and effective and timely treatment is also propelling the growth of the market. 

Restraints 

Low Awareness and Regulatory Challenges 

• In a few regions, mainly middle-income and low-income nations, individuals lack awareness of the benefits of AST. Moreover, poor training for the laboratory staff on the recent testing methods may hamper effective adoption of AST. Also, the regulatory scenario for diagnostic instruments and solutions may be complicated and consume more time. Strict regulatory needs may delay the introduction of novel AST technologies in the market. 

Growth of Alternate Testing Methods 

• The emergence of competitive and alternate diagnostic techniques like NGS next-generation sequencing and rapid molecular tests may be a barrier for the traditional antimicrobial susceptibility testing techniques. These substitutes may offer faster results, leading to decreased demand for antimicrobial susceptibility testing. Furthermore, uncertainties regarding reimbursement for AST may hamper investment in improved technologies.